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Abstract 
Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several 
cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this 
review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion, 
metastasis and therapy resistance. In particular, this review will focus on the interactions between 
cell receptor ligands and fibronectin and how this interaction influences downstream signaling 
events that aid tumor progression. This review will further discuss the possible implications of 
therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will 
additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin 
expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated 
that these studies will set a basis for future research that will not only aid understanding of 
fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics. 
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Introduction 
The extracellular matrix (ECM) is a protein rich 
entity which supports tissue structure, cell adhesion, 
cell-cell communication and differentiation [1]. 
Numerous studies have found that ECM proteins are 
aberrantly expressed in carcinomas and actively 
participate in tumor progression. In particular, 
fibronectin is receiving increasing interest as a result 
of its participation in multiple stages of tumor 
progression. Under homeostatic conditions, 
fibronectin has been shown to play a role in cell 
growth, differentiation, migration, and is additionally 
involved in processes such as wound healing and 
blood coagulation [2]. With regard to cancer, 
fibronectin is not only increased in tumors where its 
altered expression has been shown to promote tumor 
growth [3-5], migration [6, 7] and invasion [8, 9] but 
fibronectin has also been reported to limit tumor cell 
responsiveness to therapy [10-12] (Figure 1). 
Fibronectin has even been shown to alter mammary 
epithelial cell behavior. For instance, the introduction 
of fibronectin to differentiated mammary epithelial 
cell acini cultured atop the basement membrane 
extract Matrigel caused the cells to re-enter the cell 
cycle thus reversing their growth arrest and acinar 
morphology [13]. Work in our lab has shown that loss 
of caveolin-1, the main structural protein of caveolae, 
results in increased expression of fibronectin, 
tenascin-C and collagen in murine mammary glands 
(Thompson et al, unpublished data). The altered ECM 
is accompanied by changes in mammary gland 
architecture characterized by increased numbers of 
ducts that possess a larger circumference and area 
when compared to wild type controls, a result which 
may be in part related to increased fibronectin 
expression observed in the stroma (Thompson et al, 
unpublished data).  
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Figure 1: Fibronectin signaling in healthy and tumorigenic cells. In a healthy cell, fibronectin participates in the maintenance of homeostasis. Under 
pathological conditions, fibronectin is upregulated and associates with several integrin receptors, resulting in activation of various signaling cascades which ultimately 
promote tumorigenesis, metastasis and therapy resistance.  
 
The purpose of this review is to illustrate the 
mechanisms in which aberrant fibronectin expression 
influences tumorigenesis and therapy resistance. In 
particular, this review will focus on the interactions 
between cell receptor ligands and fibronectin and 
how this interaction influences downstream signaling 
events that facilitate tumor progression. Further, this 
review will highlight potential strategies whereby 
fibronectin deposition, engagement with cell surface 
receptors and activation of cell signaling pathways 
may be exploited to halt tumor progression. In this 
manner, it is with anticipation that a new generation 
of novel therapeutics may be developed to better 
combat fibronectin’s participation in tumorigenesis. 
Tumor Progression 
 Fibronectin has been shown to play a central role 
in processes associated with tumor progression. In 
particular, α5β1 integrin and fibronectin have not only 
been shown to be upregulated in tumors, but have 
also been reported to participate in tumor cell 
proliferation. For example, Nam et al found that 
fibronectin and the extra domain (ED)-A splice 
variant of fibronectin were associated with higher 
α5β1-integrin expression in malignant as opposed to 
normal breast epithelial cells cultured atop Matrigel 
[5]. Interestingly, the authors also reported that total 
fibronectin, ED-A fibronectin and α5β1-integrin was 
markedly upregulated in the malignant breast cancer 
lines but not in non-malignant breast epithelial cells 
[5]. Similarly, Mierke et al also determined that α5β1 
integrin was upregulated in MDA-MB-231 breast 
cancer cells and further demonstrated that fibronectin 
augmented the invasiveness of α5β1 expressing breast 
cancer cells cultured atop collagen hydrogels [3]. To 
investigate a mechanism responsible for 
α5β1-fibronectin in tumor growth, Mitra et al 
examined the activation of the receptor tyrosine 
kinase c-Met in human HeyA8 and SKOV3ip ovarian 
cancer cell lines following α5β1 engagement with 
fibronectin [4]. Results showed that binding of cellular 
α5β1 to fibronectin resulted in increased activation of 
the c-Met/FAK/Src signaling pathways in ovarian 
cancer cells [4]. Blocking ovarian cancer cell α5β1 
interaction with fibronectin reduced c-Met mediated 
focal adhesion kinase (FAK) and Src phosphorylation 
in vitro and in vivo and additionally reduced tumor 
weight and proliferation in xenograft tumors [4], 
suggesting that α5β1-fibronectin interactions regulate 
cell signaling pathways important for ovarian cancer 
growth. In an effort to further examine the effects of 
integrins on ovarian tumor cell proliferation, Kenny et 
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al examined adhesion and proliferation of human 
ovarian cancer cells following culture atop a 
de-cellularized ECM derived from human omental 
tumors [8]. When cultured in the presence of anti- 
α5β1, αvβ3 and RGD peptides, the authors observed 
decreased adhesion and proliferation of ovarian 
cancer cells cultured atop the de-cellularized ECM 
supporting a role for fibronectin-integrin engagement 
in ovarian cell proliferation [8].  
A defining feature of tumors is the ability of 
cancer cells to evade apoptosis. In an effort to 
delineate a role for fibronectin-integrin interactions on 
tumor cell resistance to apoptosis, Han et al used 
Wortmannin to block PI3-K in human bronchial 
epithelial BEAS-2B and 16-HBE cell lines following 
α5β1 cellular engagement with fibronectin [14]. The 
authors found that Wortmannin caused an increase in 
DNA fragmentation indicative of apoptosis [14]. In 
the absence of Wortmannin, fibronectin stimulated 
α5β1-mediated phosphorylation of PI3-K and 
downstream signaling of PI3-K/Akt, which in turn, 
down-regulated p21 and the tumor suppressor gene 
p53 and upregulated cyclin D1 in the bronchial 
epithelial cells [14]. 
In addition to integrins, fibronectin binding to 
cell surface receptors such as syndecans has been 
reported to regulate tumor cell ECM attachment and 
growth. This is evidenced by work from Huang et al 
who examined the effect of tenascin-C on tumor cell 
adhesion to fibronectin [15]. Using MDA-MB-435 
breast cancer and T98G gliobastoma cell lines, the 
authors found that tenascin-C bound to the FNIII13 of 
the HepII site on fibronectin blocked syndecan-4 
mediated tumor cell binding to fibronectin [15]. 
Overexpressing syndecan-4 reversed the effects of 
tenascin-C induced inhibition of tumor cell adhesion 
to fibronectin, suggesting that tenascin-C bound to the 
FNIII13 site on fibronectin disrupts 
syndecan-4-fibronectin signaling [15]. Similarly, 
syndecan 1 and 4 engagement with fibronectin was 
reported to promote MDA-MB-231 breast cancer cell 
adhesion and migration on collagen and proliferation 
on fibronectin matrices, an observation which was 
reversed upon incubation with anti-syndecan 1 and 4 
antibodies [16].  
Aside from direct cellular interactions with 
fibronectin on tumor progression, others have 
reported a role for fibronectin in tumor 
immunosuppression. For example, Sengupta et al 
examined the role of siRNA against fibronectin in 
glioma tumor growth and immune cell activation [17]. 
Using GL261 glioma tumor cells, the authors observed 
delayed tumor cell proliferation and growth in mice 
injected with fibronectin silenced GL261 cells [17]. 
This observation was in part, attributed to a reduction 
in the number of T-regulatory cells, which inhibit the 
activity of T helper cells.  
While the full length form of fibronectin plays an 
important role in tumorigenesis, isoforms of 
fibronectin, such as the ED-A and ED-B variants, have 
been reported to regulate tumor growth. For instance, 
Rybak et al demonstrated markedly higher expression 
of ED-A fibronectin in the vasculature of murine liver 
metastases from F9 teratocarcinoma cells with 
minimal expression observed in non-diseased organs, 
pointing to a role for ED-A fibronectin in angiogenesis 
[18]. Indeed, a later study demonstrated that ED-A 
overexpressing colorectal cancer cells exhibited 
upregulated expression of the pro-angiogenic 
cytokine vascular endothelial growth factor-C 
(VEGF-C) and promoted tumor growth and 
lymphangiogenesis in mice [19]. To determine a 
mechanism responsible for these observations, the 
authors report that ED-A upregulation of VEGF-C is 
accomplished via ED-A mediated activation of the 
PI3K/Akt pathway. Dose dependent reductions in 
VEGF-C were observed following cancer cell 
treatment with an inhibitor of PI3K [19]. Aside from a 
role in angiogenesis, ED-A fibronectin was reported to 
be upregulated in patient colorectal tumors, especially 
those that were of advanced stage [20]. Investigating 
CD133+/CD44+ colorectal tumor cells, a subset of cells 
believed to be responsible for colon cancer initiation, 
the authors found that these cells expressed higher 
levels of the ED-A receptor α9β1 and further 
demonstrated that ED-A interaction with α9β1 was 
required for tumor cell proliferation [20]. To elucidate 
a mechanism responsible for their observations, Ou et 
al found that ED-A sustains Wnt/β-catenin signaling, 
necessary for the progression of colorectal cancer 
cells, via integrin mediated activation of a FAK/ERK 
pathway [20]. In a more recent study, ED-A 
fibronectin was shown to increase the population of 
myeloid derived cells, known to impair immune 
responses to cancer cells, from osteoblasts [21]. To 
determine whether the absence of fibronectin 
impaired myeloid cell numbers and thus tumor 
formation, the authors subcutaneously injected 
melanoma cells into either a fibronectin knock out 
model (cKO) in which fibronectin expression in 
differentiating osteoblasts was conditionally deleted 
or a wild type animal (WT) and evaluated for tumor 
formation [21]. Tumor growth and the presence of 
myeloid cells in tumors were reduced in cKO animals 
but not in WT animals [21]. Although the authors 
don’t attribute these findings to a specific reduction in 
the ED-A fibronectin isoform, they go on to 
demonstrate that culture of myeloid cells from cKO 
animals with ED-A fibronectin resulted in a reduction 
of melanoma apoptosis, suggesting that this 
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pro-tumor effect results from ED-A activation of 
myeloid cells [21]. 
ED-B fibronectin has also been reported to play a 
role in angiogenesis where it has been shown to 
promote VEGF expression, tube formation and 
proliferation of human vascular endothelial cells [22]. 
Specifically, the authors found that ED-B fibronectin 
was upregulated in vascular endothelial cells in 
response to high glucose, TGF-β1 and endothelin-1, a 
finding which was reversed following administration 
of inhibitors to TGF-β1 and endothelin-1 [22]. These 
findings would suggest that growth factor signaling is 
an important regulator of ED-B fibronectin mediated 
vascular morphogenesis [22]. Despite a role in 
angiogenesis, ED-B fibronectin expression has been 
documented to be more highly expressed in the 
stromal and epithelial compartments of colorectal and 
breast carcinomas, but not in endothelial cells [23], 
suggesting that additional work is needed in order to 
fully elucidate the role of ED-B fibronectin in 
tumorigenesis. Regardless of its role in tumorigenesis, 
ED-B fibronectin has more recently been exploited as 
a molecular marker for prostate cancer. Here, Han et al 
synthesized a small peptide to target upregulated 
ED-B expression in tumor xenografts harboring 
human prostate carcinomas, demonstrating that the 
peptide bound to ED-B fibronectin produced by the 
tumor cells [24]. It’s conceivable that this strategy may 
be utilized for both imaging and diagnostic purposes 
as well as delivery of therapeutics.  
Overall, these studies suggest that fibronectin, 
via engagement with several integrin receptors and 
interference with immune function, favors tumor cell 
survival and proliferation. Additionally, multiple 
isoforms of fibronectin also participate in 
tumorigenesis, highlighting the importance of 
understanding how the different splice variants of 
fibronectin not only interact with cell surface 
receptors, but how this interaction activates 
downstream signaling pathways important for tumor 
growth.  
Tumor Invasion and Metastasis 
  While fibronectin appears to play a key 
role in multiple facets of tumor progression, it has also 
been shown to participate in processes associated 
with tumor migration, invasion and metastasis. To 
examine the role of fibronectin on tumor cell 
migration, Lou et al overexpressed SOX2 to determine 
its role in ovarian tumor cell metastasis [6]. Here, the 
overexpression of SOX2 upregulated fibronectin gene 
expression resulting in increased migration and 
invasion of the A2780 human ovarian cancer cell line 
in transwell chambers [6]. Downregulation of 
fibronectin using siRNA resulted in a reversal of cell 
migration and invasion despite high expression of 
SOX2 indicating that SOX2 signals via fibronectin 
during tumor cell metastasis [6]. To further explore 
the role of fibronectin on tumor cell migration, Wei et 
al sought to demonstrate whether nicotine enhanced 
the migration of SW480 colorectal cancer cells through 
nicotinic-acetylcholine receptor (7-nAChR) mediated 
induction of COX-2 [7], reported to regulate EMT [25]. 
The authors found that inhibiting 7-nAChR and 
COX-2 not only limited fibronectin expression, but 
also increased E-cadherin expression, reducing SW480 
cell migration [7]. In the absence of COX-2 inhibition, 
nicotine enhanced colon cancer cell migration via 
7-nAChR and COX-2 mediated up-regulation of 
fibronectin expression indicating that inhibition of 
COX-2 and 7-nAChR reduced migration of colorectal 
cancer cells as a result of a reduction in fibronectin 
expression [7].  
Integrin engagement has been reported to play a 
crucial role in fibronectin mediated tumor cell 
invasion. A recent study reported an indispensable 
role for fibronectin and the α5β1 integrin on the 
invasive capabilities of HeyA8 and SKOV3ip1 human 
ovarian cancer cell lines [8]. Here, the authors first 
showed that 3D co-culture of ovarian cancer cells with 
mesothelial cells supported fibronectin expression 
from mesothelial cells via activation of a 
TGF-βR1/RAC1/SMAD3 signaling pathway, a 
phenomenon which was important for cancer cell 
adhesion, proliferation and invasion as silencing of 
fibronectin reduced these cellular responses [8]. In an 
attempt to further elucidate a role for fibronectin in 
tumor cell progression, the authors administered 
antibodies against α5 and β1 integrins to 3D 
co-cultures of ovarian cancer cells and mesothelial 
cells and discovered that tumor cell invasion and 
proliferation was reduced up to 40% [8]. In-vivo, the 
authors found that treatment of mice with antibodies 
against α5 and β1 reduced the number of metastases 
and tumor weight from orthotopically injected 
ovarian cancer cell lines [8]. These results suggest that 
ovarian cancer cells stimulate fibronectin expression 
from mesothelial cells via a TGF-β pathway and that 
tumor cells adhere, proliferate and invade in response 
to α5 and β1 integrin engagement with fibronectin. In a 
similar study, it was shown that inhibition of α5 and 
β1 integrins significantly reduced ovarian tumor cell 
adhesion to a 3D model consisting of primary human 
mesothelial cells and fibroblasts and additionally 
limited the number of metastases in ovarian cancer 
xenografts [26]. Downregulation of E-cadherin on 
ovarian cancer cells was specifically shown to 
augment α5 integrin expression via activation of FAK 
and Erk1 [26]. Further, siRNA of E-cadherin was 
shown to increase cancer cell adhesion to fibronectin 
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and invasion in a Matrigel matrix [26], suggesting that 
ovarian cancer cell adhesion to fibronectin and 
invasion in a 3D matrix are regulated by decreased 
E-cadherin mediated α5 integrin expression. In 
addition to ovarian cancer, work by others have 
shown that MDA-MB-231 breast cancer, T24 bladder 
carcinoma, and 786-O renal adenocarcinoma cells 
expressing α5β1 integrins exhibited increased invasion 
in 3D collagen matrices which had been polymerized 
with fibronectin, further highlighting that integrin 
engagement with fibronectin supports tumor cell 
invasion in 3D [3]. Interestingly, the addition of 
soluble fibronectin at the start of the assay reduced 
tumor cell invasion in collagen matrices, suggesting 
that differences in the polymerization status of 
fibronectin may differentially regulate tumor cell 
behavior [3]. A role for αvβ3 interaction with 
fibronectin has also been reported to participate in 
tumor cell invasiveness. For example, 3D matrices of 
clotted plasma, reported to play an important role in 
tumor metastasis [27], or fibrin, the principal 
component of clots, were found to induce 
invadopodia, cellular protrusions which participate in 
the early stages of cell migration and invasion, 
formation from several tumor cell lines [9]. 
Invadopodia were associated with increased 
expression of αvβ3 integrin and fibronectin matrix 
formation [9]. Furthermore, it was found that primary 
metastatic kidney tumor cells exhibited an increased 
expression of invadopodia formation in addition to 
fibronectin and αvβ3 integrin which together 
upregulated the expression of the 
epithelial-mesenchymal (EMT) transcription factor 
Slug [9]. These results would suggest that αvβ3 and 
fibronectin promote tumor cell invadopodia 
formation via activation of the EMT transcription 
factor Slug. 
In order to metastasize to distant sites, tumor 
cells make use of altered cell signaling pathways and 
matrix metalloproteinases (MMPs), which degrade 
and remodel the ECM allowing tumor cell migration. 
With regard to a role for fibronectin in altered cell 
signaling, Balanis et al showed that adhesion of 
MDA-MB-231 breast cancer cells to fibronectin 
elicited robust STAT3 activation, a result which was 
dependent on cellular expression of FAK and the 
tyrosine kinase PYK2 [28]. The authors further 
demonstrated that administration of fibronectin to 
MDA-MB-231 cells cultured atop 3D hydrogels 
resulted in cellular outgrowth and a phenotype 
previously linked with enhanced metastatic 
properties [28]. Inhibition of β1 integrin or the use of a 
small inhibitor against STAT3 reversed these findings, 
suggesting that in 3D, MDA-MB-231 breast cancer 
cells utilize fibronectin-β1 integrin mediated STAT3 
signaling during invasion [28]. To illustrate a 
cooperative role of fibronetin and MMPs in tumor 
invasion, Meng et al sought to determine whether 
A549 lung cancer cell invasion occurred as a result of 
fibronectin-induced FAK activation of MMP9 [29]. 
The authors found that fibronectin stimulated FAK 
phosphorylation and Src recruitment, resulting in 
activation of downstream targets, ERK1/2 and 
PI3K/Akt in A549 cells, promoting invasion and 
migration of the cancer cells in transwell chambers 
[29]. Inhibition of ERK1/2 and PI3K resulted in a 
reduction of migrating and invasive A549 cells as a 
result of downregulation of MMP9, implicating a role 
for fibronectin-FAK-MMP9 in lung cancer invasion 
[29]. Together, these findings not only suggest an 
important role for integrin engagement with 
fibronectin, but cooperation between fibronectin and 
altered cell signaling and MMP expression in 
processes associated with tumor invasion and 
metastasis.  
Therapy Resistance  
Chemotherapeutic agents have undoubtedly 
contributed to improved survival rates for individuals 
with cancer. Despite these successes, tumor cell 
resistance to therapies and relapse are still a common 
feature of the disease. While a number of factors have 
been implicated in chemotherapy resistance, 
fibronectin has received interest. In a study by 
Pontiggia et al the efficacy of tamoxifen, an estrogen 
receptor antagonist, was used to examine how the 
microenvironment limits tumor cell sensitivity to 
tamoxifen [12]. Here, the authors co-incubated human 
and mouse breast tumor cells with fibronectin and 
measured tumor cell sensitivity to tamoxifen [12]. The 
addition of fibronectin promoted tamoxifen resistance 
via fibronectin-mediated activation of β1-integrin 
which in turn, stimulated the PI3K/Akt and 
MAPK/Erk 1/2 signaling pathways in both tumor 
cell lines [12]. Disrupting the interaction between the 
β1-integrin and fibronectin reversed the conferred 
resistance, leading to drug-induced apoptosis of the 
tumor cells [12]. Similarly, Yuan et al found that β1 
integrin and fibronectin were markedly increased in 
tamoxifen resistant as opposed to tamoxifen sensitive 
MCF7 breast cancer cells [30]. The overexpression of 
β1 was associated with increased expression of the 
epidermal growth factor receptor (EGFR)/ERK 
signaling pathway. Inhibition of β1 improved 
tamoxifen sensitivity of resistant MCF7 cells and 
further reduced cellular migration following culture 
in the presence of conditioned media from carcinoma 
associated fibroblasts (CAFs) [30]. Interestingly, 
culture of tamoxifen resistant MCF7 cells in CAF 
conditioned media resulted in enhanced cell 
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migration due to CAF produced fibronectin, a result 
which was diminished following cellular treatment 
with the β1 integrin inhibitor [30]. In addition to 
tamoxifen, cetuximab, an antibody that inhibits cell 
proliferation when bound to the EGFR, has been 
reported to have limited efficacy as a result of tumor 
cell resistance [10]. For example, A549 human lung 
adenocarcinoma cells and H1299 human non-small 
cell lung carcinoma cells were reported to have 
diminished cell cytotoxicity to cetuximab and 
radiation following culture atop fibronectin coated 
surfaces [10]. The observed reduction of cytotoxicity 
was a result of tumor cell α5β1 integrin engagement 
with fibronectin as silencing these integrins restored 
tumor cell sensitivity to cetuximab [10]. Interestingly, 
cetuximab was also shown to promote increased 
fibronectin expression from both tumor cell lines, a 
finding which was reported to result from activation 
of the p38-MAPK-ATF2 signaling pathway [10]. 
siRNA silencing of fibronectin improved cytotoxicity 
of cetuximab in H1299 and A549 tumor cell lines, 
demonstrating that excess fibronectin in combination 
with α5β1 integrin engagement with fibronectin 
facilitates cetuximab resistance [10]. In a similar study, 
changes in tumor cell apoptosis were analyzed 
following etoposide treatment of H69 small cell lung 
cancer cells which had been cultured in fibronectin 
coated dishes [31]. The results showed that tumor cell 
α2, α3, α6, and β1 integrin interaction with fibronectin 
inhibited chemotherapy induced apoptosis, 
evidenced by decreased caspase 3-activity [31]. Using 
breast cancer as a model, Spangenberg et al reported 
that inducible expression of the ERBB2 
proto-oncogene in MCF7 breast cancer cells resulted 
in upregulated gene expression of α5 and β1 integrins 
[32]. The authors found that MCF7 cells exhibited 
increased resistance to cisplatin and 5-fluorouracil as 
a result of ERBB2 induced α5β1 integrin expression 
and exhibited a 2 fold reduction in responsiveness to 
these agents when the cells were cultured on 
fibronectin. To overcome chemotherapy resistance 
from integrin-fibronectin interactions, Nam et al 
showed that disrupting the peptide bond between 
fibronectin and α5β1-integrin in combination with 
radiation therapy promoted apoptosis and reduced 
the expression of α5β1 in cultures of malignant human 
breast cancer cells cultured atop a 3D Matrigel [5]. The 
authors found that the pro-survival effect of 
malignant tumor cell α5β1 interaction with fibronectin 
in a 3D environment was a result of α5β1 mediated 
activation of Akt signaling as Akt kinase and Akt 
phosphorylation were downregulated following α5β1 
inhibition [5]. Similarly, it was found that primary 
glioblastomas resistant to the anti-angiogenic agent 
bevacizumab exhibited a higher expression of β1 
integrins and FAK, a phenomenon the authors 
attributed to high intra-tumoral hypoxia following 
anti-angiogenic therapy [33]. To determine whether 
inhibition of β1 integrin improved therapeutic 
responses, the authors treated subcutaneously grown 
U87MG glioblastomas with alternating doses of a β1 
inhibitor and low dose (1mg/kg) bevacizumab [33]. 
The results showed a significant improvement in 
tumor regression in the dual treated animals [33]. 
These results were comparable to a high dose regimen 
(10mg/kg) of bevacizumab alone, suggesting that the 
addition of a β1 integrin inhibitor improves the 
therapeutic efficiency of bevacizumab [33]. Figure 2 
provides a graphical summary of the findings 
addressed above. Given these and other similar 
studies, it’s apparent that targeting the cellular 
interactions with fibronectin and/or fibronectin itself 
may be a desirable strategy to improve patient 
outcomes.  
 
 
 
Figure 2: Integrin-fibronectin interaction in tumor therapy 
responses. (A) Tumor cell α5β1 or β1 integrin interaction with fibronectin 
results in activation of cell signaling pathways which ultimately culminate in 
tumor cell resistance to chemotherapeutic agents. (B) Inhibition of α5β1 or β1 
integrin interaction with fibronectin restores tumor cell sensitivity to 
chemotherapeutic agents resulting in increased cytotoxicity. 
 
Future Outlook: Potential Strategies for 
Targeting Fibronectin 
 While the aforementioned studies have 
provided encouraging evidence to address 
therapeutic targets against integrin engagement with 
fibronectin, further research is necessary in order to 
find novel strategies for inhibiting tumor growth via 
targeting fibronectin biosynthesis and/or fibronectin 
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regulated cell signaling.  
Matrix rigidity is a common feature of tumors 
and has been shown to support tumor growth, 
invasion and metastasis [34]. In response to matrix 
rigidity, focal adhesions, complexes of integrin 
receptors which facilitate cellular attachments with 
the ECM, are formed. FAK, a structural and signaling 
component of focal adhesions, has not only been 
reported to be upregulated in response to matrix 
rigidity [35], but has additionally been shown to 
regulate fibronectin-directed matrix fibrillar 
organization [36]. For instance, Ilic et al reported that 
fibronectin fibrils were more sparse and thinner in 
FAK null embryos compared to wildtype littermates 
and fibroblasts, a result which was demonstrated to 
be independent of fibronectin gene or protein 
expression and synthesis, suggesting that FAK 
activity is necessary for fibronectin matrix 
organization [36]. Interestingly, in a separate study, 
fibronectin expression was shown to drive FAK 
signaling [29], suggesting that both FAK and 
fibronectin may interact in a positive feedback loop. 
Given the role of FAK in fibronectin expression, it’s 
conceivable that targeting FAK expression may be a 
mechanism to reduce fibronectin expression and thus 
tumor progression. Meng et al showed that 
fibronectin-induced FAK tumor cell migration and 
invasion was decreased following treatment of A549 
lung tumor cells with the Src inhibitor PP2 [29]. 
Specifically, the authors reported that inhibition of Src 
resulted in decreased FAK phosphorylation 
suggesting that a reduction of FAK activity may be a 
useful strategy to reduce fibronectin mediated effects 
on tumor cell migration and invasion [29]. In addition 
to indirect targets of FAK, it may be possible to 
directly reduce FAK activity via use of a novel ATP 
competitive kinase inhibitor, PF-04554878, which was 
recently shown to promote apoptosis and reduce 
proliferation of pancreatic neuroendocrine tumor cells 
[37].  
Aside from targeting FAKs, it may be possible to 
directly reduce matrix stiffness in tumors, thereby 
preventing FAK-induced fibronectin expression. 
Levental et al demonstrated that expression of lysyl 
oxidase (LOX), an enzyme which cross-links collagen 
fibers [38], not only increased FAK expression, but 
augmented matrix rigidity and breast tumor 
progression, a phenomenon which was reversed upon 
treatment with an inhibitor of LOX [39]. In support of 
a role for LOX in fibronectin expression, Adam et al 
showed that atrial samples from patients with atrial 
fibrillation exhibited increased expression of LOX and 
fibronectin [40]. Administration of a small molecule 
inhibitor of LOX to neonatal cardiac fibroblasts 
attenuated LOX-induced fibronectin expression via 
downregulation of angiotensin II and connective 
tissue growth factor [40]. Although this work was 
conducted in cardiac fibroblasts, it’s foreseeable that 
inhibiting LOX may be a means to reduce tumoral 
fibronectin expression. Overall, it is likely that 
targeting the molecular machinery which is 
responsible for supporting matrix rigidity will reduce 
both fibrosis and fibronectin expression and in effect 
decrease tumor progression.  
 While indirect targets against fibronectin should 
undoubtedly yield more favorable outcomes for 
cancer patients, it would be ideal to directly target the 
biosynthesis of fibronectin. To this end, 
Tomasini-Johansson et al developed a small peptide 
inhibitor of fibronectin, pUR4B, which was shown to 
limit fibronectin polymerization in the matrix [41]. 
Work by Chiang et al has shown that administration 
of pUR4B in animals which had received a partial 
ligation of the external or internal carotid arteries 
resulted in reduction of intima, media and adventitial 
thickness of the vessels and further decreased the 
accumulation of fibronectin and collagen [42]. 
Furthermore, Hielscher et al demonstrated that 
treatment of co-cultures of fibroblasts and breast 
cancer cells with pUR4B not only reduced fibronectin 
deposition and organization in the ECM, but also 
inhibited the deposition of other matrix proteins [43]. 
Additionally, inhibition of fibronectin matrix 
assembly also attenuated vascular morphogenesis of 
endothelial cells cultured atop the 
fibronectin-deficient matrix [43]. These studies 
illustrate that fibronectin not only serves as a 
substrate regulating the assembly of other ECM 
proteins but is additionally important for supporting 
angiogenesis. As such, direct inhibition of fibronectin 
polymerization via a small peptide may impair the 
assembly of other matrix proteins and capillaries, thus 
depriving tumors of a supportive scaffold and the 
oxygen and nutrients necessary for continued growth. 
Indeed, the use of such anti-cancer peptides have not 
only been used to directly treat cancer but have also 
been used as cytotoxic drug carriers [44]. As such, it’s 
possible that delivery of a peptide inhibitor of 
fibronectin polymerization may be utilized in 
conjunction with a chemotherapy regimen to improve 
outcomes for cancer patients. A benefit from use of an 
inhibitor of fibronectin polymerization is that the off 
target effects of the peptide should be minimal as 
fibronectin isn’t actively produced in tissues with the 
exception of wounds and during development. One 
drawback may be concentrating the peptide to 
achieve maximal responses. As such, one may need to 
complex the inhibitor in a delivery vector to improve 
both tumor targeting and sustained delivery of the 
peptide at the tumor site.  
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RNA interference is rapidly becoming a 
powerful tool to silence the expression of genes and 
has been extensively investigated for its utility as a 
form of cancer therapy. Previous studies have shown 
that silencing fibronectin reduced tumor cell 
proliferation and growth [17] and tumor cell 
migration [6]. As such, silencing fibronectin gene 
expression via RNA silencing may be an effective 
strategy to enhance therapeutic responses. Despite its 
obvious advantages, the major drawback associated 
with use of gene based therapies is the delivery of 
these to the tumor. Traditionally, siRNA have been 
delivered locally where they’ve had much success 
with regard to treating ocular diseases [45]. For 
delivery of fibronectin siRNA to tumors, it will be 
important to utilize vectors which not only target the 
tumor, but penetrate the tumor cell membrane to 
deliver the packaged siRNA particles. 
Cell-penetrating peptides (CPP), which consist of 
short peptide sequences of 10-30 amino acids, have 
been shown to cross the cellular plasma membrane 
[46]. Derived from viral proteins or mammalian 
proteins with translocation capabilities, CPPs have 
been used to deliver siRNA to in-vitro cell cultures 
[47] and in transvascular delivery of siRNA to mice 
[48]. Although additional work will be necessary, the 
use of these vectors may be an avenue by which to 
deliver fibronectin siRNA to tumors.  
Another means by which to target fibronectin 
expression could come from use of vaccinia viruses, 
double stranded DNA viruses used to treat cancer. 
Use of vaccinia viruses has received increased interest 
as strategies to engineer more potent oncolytic forms 
of vaccinia viruses has not only resulted in greater 
tumor specificity but have been shown to be an 
efficient means by which to lyse tumor cells [49]. 
Recently, a genetically engineered vaccinia virus was 
reported to target both malignant ovarian cancer cells 
in addition to the fibroblasts in the tumor stroma [50]. 
Given that the vaccinia virus was able to infect 
fibroblasts, it’s possible that utilizing a similar 
strategy may halt the production of fibronectin from 
cancer associated fibroblasts as fibroblasts are a 
principle cell type responsible for ECM production.  
 Together, the aforementioned studies have 
provided a clearer perspective on the mechanisms 
whereby fibronectin exerts its tumorigenic effects in 
cancer. These studies suggest that fibronectin is not 
only aberrantly expressed in tumors, but also 
promotes tumor progression, metastasis and therapy 
resistance via activation of a number of downstream 
signaling pathways. With advances in this 
knowledge, it’s foreseeable that employing strategies 
to inhibit tumor cell association with fibronectin, 
fibronectin-mediated cell signaling and/or fibronectin 
biosynthesis in the ECM will not only result in 
unprecedented discoveries about the mechanisms 
fibronectin exerts on tumor cell behavior, but will 
additionally result in development of novel 
therapeutic approaches to treat cancer.  
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